Medicines and Healthcare products Regulatory Agency(MHRA)
The United Kingdom's regulatory agency for medicines, medical devices, and blood components.
Usage Examples
- The MHRA authorized the product via the International Recognition Procedure based on FDA approval.
- UKCA marking was obtained alongside continued CE mark use for the Class II device.
What is MHRA?
MHRA is the UK's sovereign regulator for medicines, medical devices, and blood components, operating as an executive agency of the Department of Health and Social Care. Post-Brexit (2021), MHRA gained full independent regulatory authority previously shared with EMA. UK marketing authorization can be obtained through multiple routes: standalone UK MA, the International Recognition Procedure (IRP) leveraging approvals from specified reference regulators (FDA, EMA, Health Canada, TGA, Swissmedic, Singapore HSA), and ongoing access via the Northern Ireland Protocol.
The Innovative Licensing and Access Pathway (ILAP) provides rolling review and enhanced engagement for innovative medicines. UK medical device regulation is transitioning — current devices use UKCA marking alongside continued CE mark acceptance through 2028-2030 depending on device type. Post-market pharmacovigilance uses the Yellow Card Scheme for adverse event reporting.
Regulatory Context
This term appears most often in general workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside UK MEDICINES ACT, UK HMR 2012.
When This Matters
- The MHRA authorized the product via the International Recognition Procedure based on FDA approval.
- UKCA marking was obtained alongside continued CE mark use for the Class II device.
Common Mistakes
- Relying on generic terminology without mapping to the active jurisdiction context.
- Skipping cross-links between terms, tools, and active regulatory references.
- Failing to maintain a single source of truth for regulatory definitions internally.
Related Regulations
Frequently Asked Questions
MHRA operates as an independent sovereign regulator since January 2021. EMA covers the EU-27; MHRA covers Great Britain (Northern Ireland still follows EU rules for medicines per the Windsor Framework). The two regulators are separate but often align on scientific positions.
MHRA's IRP enables UK authorization via reliance on approvals from specified reference regulators (FDA, EMA, Health Canada, TGA, Swissmedic, Singapore HSA). Review times are reduced (60-110 days depending on recognition type). Launched January 2024.
Currently yes, with transition deadlines extending acceptance of EU CE marking through 2028-2030 depending on device type. New UKCA marking is available but not yet mandatory for most devices.
Related Terms
Related Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
Track GxP regulation changes and enforcement trends
Related Regulatory Intelligence
Related Actions
Sources & References
